135 related articles for article (PubMed ID: 37227014)
1. Split AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1).
Li R; Jing Q; She K; Wang Q; Jin X; Zhao Q; Su J; Song L; Fu J; Wu X; Xu Q; Lu F; Wei Y; Yang Y
Hum Gene Ther; 2023 Jul; 34(13-14):616-628. PubMed ID: 37227014
[TBL] [Abstract][Full Text] [Related]
2. Dual
Dyka FM; Molday LL; Chiodo VA; Molday RS; Hauswirth WW
Hum Gene Ther; 2019 Nov; 30(11):1361-1370. PubMed ID: 31418294
[TBL] [Abstract][Full Text] [Related]
3. An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult
McClements ME; Barnard AR; Singh MS; Charbel Issa P; Jiang Z; Radu RA; MacLaren RE
Hum Gene Ther; 2019 May; 30(5):590-600. PubMed ID: 30381971
[TBL] [Abstract][Full Text] [Related]
4. Dual AAV Vectors for Stargardt Disease.
Trapani I
Methods Mol Biol; 2018; 1715():153-175. PubMed ID: 29188512
[TBL] [Abstract][Full Text] [Related]
5. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease.
Trapani I; Toriello E; de Simone S; Colella P; Iodice C; Polishchuk EV; Sommella A; Colecchi L; Rossi S; Simonelli F; Giunti M; Bacci ML; Polishchuk RS; Auricchio A
Hum Mol Genet; 2015 Dec; 24(23):6811-25. PubMed ID: 26420842
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for Stargardt disease associated with ABCA4 gene.
Han Z; Conley SM; Naash MI
Adv Exp Med Biol; 2014; 801():719-24. PubMed ID: 24664763
[TBL] [Abstract][Full Text] [Related]
7. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease.
Lenis TL; Sarfare S; Jiang Z; Lloyd MB; Bok D; Radu RA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3987-3992. PubMed ID: 28348233
[TBL] [Abstract][Full Text] [Related]
8. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy.
Kong J; Kim SR; Binley K; Pata I; Doi K; Mannik J; Zernant-Rajang J; Kan O; Iqball S; Naylor S; Sparrow JR; Gouras P; Allikmets R
Gene Ther; 2008 Oct; 15(19):1311-20. PubMed ID: 18463687
[TBL] [Abstract][Full Text] [Related]
9. Impaired cathepsin D in retinal pigment epithelium cells mediates Stargardt disease pathogenesis.
Ng ESY; Hu J; Jiang Z; Radu RA
FASEB J; 2024 Jun; 38(11):e23720. PubMed ID: 38837708
[TBL] [Abstract][Full Text] [Related]
10. Non-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles.
Sun D; Schur RM; Sears AE; Gao SQ; Vaidya A; Sun W; Maeda A; Kern T; Palczewski K; Lu ZR
Mol Ther; 2020 Jan; 28(1):293-303. PubMed ID: 31611143
[TBL] [Abstract][Full Text] [Related]
11. ABCA4-Associated Stargardt Disease.
Khan M; Cremers FPM
Klin Monbl Augenheilkd; 2020 Mar; 237(3):267-274. PubMed ID: 32016942
[TBL] [Abstract][Full Text] [Related]
12. Gene Therapy of ABCA4-Associated Diseases.
Auricchio A; Trapani I; Allikmets R
Cold Spring Harb Perspect Med; 2015 Jan; 5(5):a017301. PubMed ID: 25573774
[TBL] [Abstract][Full Text] [Related]
13. Novel variants of ABCA4 in Han Chinese families with Stargardt disease.
Hu FY; Gao FJ; Li JK; Xu P; Wang DD; Zhang SH; Wu JH
BMC Med Genet; 2020 Oct; 21(1):213. PubMed ID: 33129279
[TBL] [Abstract][Full Text] [Related]
14. Assessment of AAV Dual Vector Safety in the
McClements ME; Barnard AR; Charbel Issa P; MacLaren RE
Transl Vis Sci Technol; 2020 Jun; 9(7):20. PubMed ID: 32724727
[TBL] [Abstract][Full Text] [Related]
15. The genetic architecture of Stargardt macular dystrophy (STGD1): a longitudinal 40-year study in a genetic isolate.
Green JS; O'Rielly DD; Pater JA; Houston J; Rajabi H; Galutira D; Benteau T; Sheaves A; Abdelfatah N; Bautista D; Whelan J; Young TL
Eur J Hum Genet; 2020 Jul; 28(7):925-937. PubMed ID: 32467599
[TBL] [Abstract][Full Text] [Related]
16. An augmented ABCA4 screen targeting noncoding regions reveals a deep intronic founder variant in Belgian Stargardt patients.
Bauwens M; De Zaeytijd J; Weisschuh N; Kohl S; Meire F; Dahan K; Depasse F; De Jaegere S; De Ravel T; De Rademaeker M; Loeys B; Coppieters F; Leroy BP; De Baere E
Hum Mutat; 2015 Jan; 36(1):39-42. PubMed ID: 25346251
[TBL] [Abstract][Full Text] [Related]
17. Stargardt macular dystrophy and therapeutic approaches.
Fujinami K; Waheed N; Laich Y; Yang P; Fujinami-Yokokawa Y; Higgins JJ; Lu JT; Curtiss D; Clary C; Michaelides M
Br J Ophthalmol; 2024 Mar; 108(4):495-505. PubMed ID: 37940365
[TBL] [Abstract][Full Text] [Related]
18. Functional Characterization of ABCA4 Missense Variants Linked to Stargardt Macular Degeneration.
Garces FA; Scortecci JF; Molday RS
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375396
[TBL] [Abstract][Full Text] [Related]
19. Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5.
Parker MA; Erker LR; Audo I; Choi D; Mohand-Said S; Sestakauskas K; Benoit P; Appelqvist T; Krahmer M; Ségaut-Prévost C; Lujan BJ; Faridi A; Chegarnov EN; Steinkamp PN; Ku C; da Palma MM; Barale PO; Ayelo-Scheer S; Lauer A; Stout T; Wilson DJ; Weleber RG; Pennesi ME; Sahel JA; Yang P
Am J Ophthalmol; 2022 Aug; 240():285-301. PubMed ID: 35248547
[TBL] [Abstract][Full Text] [Related]
20. Inclusion of a degron reduces levelsof undesired inteins after AAV-mediated protein
Tornabene P; Trapani I; Centrulo M; Marrocco E; Minopoli R; Lupo M; Iodice C; Gesualdo C; Simonelli F; Surace EM; Auricchio A
Mol Ther Methods Clin Dev; 2021 Dec; 23():448-459. PubMed ID: 34786437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
